Py, a novel oral irreversible tyrosine kinase inhibitor (TKI) targeting HER1, HER2, and HER4, was initially approved in China for the treatment of HER2-positive advanced or metastatic BC in 2018. The gene discussed is EGFR; the disease is breast cancer.